These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 8630044)

  • 1. Nonpeptidic HIV protease inhibitors: 4-hydroxy-pyran-2-one inhibitors with functional tethers to P1 phenyl ring to reach S3 pocket of the enzyme.
    Vara Prasad J; Tummino PJ; Ferguson D; Saunders J; Vander Roest S; McQuade TJ; Heldsinger A; Reyner EL; Stewart BH; Guttendorf RJ; Para KS; Lunney EA; Gracheck SJ; Domagala JM
    Biochem Biophys Res Commun; 1996 Apr; 221(3):815-20. PubMed ID: 8630044
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nonpeptidic potent HIV-1 protease inhibitors: (4-hydroxy-6-phenyl-2-oxo-2H- pyran-3-yl)thiomethanes that span P1-P2' subsites in a unique mode of active site binding.
    Prasad JV; Para KS; Tummino PJ; Ferguson D; McQuade TJ; Lunney EA; Rapundalo ST; Batley BL; Hingorani G; Domagala JM
    J Med Chem; 1995 Mar; 38(6):898-905. PubMed ID: 7699705
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nonpeptidic potent HIV-1 protease inhibitors.
    Prasad JV; Lunney EA; Para KS; Tummino PJ; Ferguson D; Hupe D; Domagala JM; Erickson JW
    Drug Des Discov; 1996 Apr; 13(3-4):15-28. PubMed ID: 8874041
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 4-hydroxy-5,6-dihydropyrones. 2. Potent non-peptide inhibitors of HIV protease.
    Tait BD; Hagen S; Domagala J; Ellsworth EL; Gajda C; Hamilton HW; Prasad JV; Ferguson D; Graham N; Hupe D; Nouhan C; Tummino PJ; Humblet C; Lunney EA; Pavlovsky A; Rubin J; Gracheck SJ; Baldwin ET; Bhat TN; Erickson JW; Gulnik SV; Liu B
    J Med Chem; 1997 Nov; 40(23):3781-92. PubMed ID: 9371244
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structure-based design of novel HIV protease inhibitors: carboxamide-containing 4-hydroxycoumarins and 4-hydroxy-2-pyrones as potent nonpeptidic inhibitors.
    Thaisrivongs S; Watenpaugh KD; Howe WJ; Tomich PK; Dolak LA; Chong KT; Tomich CC; Tomasselli AG; Turner SR; Strohbach JW
    J Med Chem; 1995 Sep; 38(18):3624-37. PubMed ID: 7658450
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nonpeptidic HIV protease inhibitors possessing excellent antiviral activities and therapeutic indices. PD 178390: a lead HIV protease inhibitor.
    Prasad JV; Boyer FE; Domagala JM; Ellsworth EL; Gajda C; Hamilton HW; Hagen SE; Markoski LJ; Steinbaugh BA; Tait BD; Humblet C; Lunney EA; Pavlovsky A; Rubin JR; Ferguson D; Graham N; Holler T; Hupe D; Nouhan C; Tummino PJ; Urumov A; Zeikus E; Zeikus G; Gracheck SJ; Erickson JW
    Bioorg Med Chem; 1999 Dec; 7(12):2775-800. PubMed ID: 10658583
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structure-based design of HIV protease inhibitors: 5,6-dihydro-4-hydroxy-2-pyrones as effective, nonpeptidic inhibitors.
    Thaisrivongs S; Romero DL; Tommasi RA; Janakiraman MN; Strohbach JW; Turner SR; Biles C; Morge RR; Johnson PD; Aristoff PA; Tomich PK; Lynn JC; Horng MM; Chong KT; Hinshaw RR; Howe WJ; Finzel BC; Watenpaugh KD
    J Med Chem; 1996 Nov; 39(23):4630-42. PubMed ID: 8917652
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A quantitative structure-activity relationship study on some sulfolanes and arylthiomethanes acting as HIV-1 protease inhibitors.
    Gupta SP; Babu MS; Sowmya S
    Bioorg Med Chem; 1998 Nov; 6(11):2185-92. PubMed ID: 9881109
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structure-based design of novel HIV protease inhibitors: sulfonamide-containing 4-hydroxycoumarins and 4-hydroxy-2-pyrones as potent non-peptidic inhibitors.
    Thaisrivongs S; Janakiraman MN; Chong KT; Tomich PK; Dolak LA; Turner SR; Strohbach JW; Lynn JC; Horng MM; Hinshaw RR; Watenpaugh KD
    J Med Chem; 1996 Jun; 39(12):2400-10. PubMed ID: 8691434
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quantitative structure-activity relationships of some HIV-protease inhibitors.
    Gupta SP; Babu MS; Kaw N
    J Enzyme Inhib; 1999; 14(2):109-23. PubMed ID: 10445038
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 4-hydroxy-5,6-dihydro-2H-pyran-2-ones.3. Bicyclic and hetero-aromatic ring systems as 3-position scaffolds to bind to S1' and S2' of the HIV-1 protease enzyme.
    Ellsworth EL; Domagala J; Prasad JV; Hagen S; Ferguson D; Holler T; Hupe D; Graham N; Nouhan C; Tummino PJ; Zeikus G; Lunney EA
    Bioorg Med Chem Lett; 1999 Jul; 9(14):2019-24. PubMed ID: 10450973
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structure-based design of nonpeptidic HIV protease inhibitors from a cyclooctylpyranone lead structure.
    Romines KR; Watenpaugh KD; Howe WJ; Tomich PK; Lovasz KD; Morris JK; Janakiraman MN; Lynn JC; Horng MM; Chong KT
    J Med Chem; 1995 Oct; 38(22):4463-73. PubMed ID: 7473573
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 4-Hydroxy-5,6-dihydropyrones as inhibitors of HIV protease: the effect of heterocyclic substituents at C-6 on antiviral potency and pharmacokinetic parameters.
    Hagen SE; Domagala J; Gajda C; Lovdahl M; Tait BD; Wise E; Holler T; Hupe D; Nouhan C; Urumov A; Zeikus G; Zeikus E; Lunney EA; Pavlovsky A; Gracheck SJ; Saunders J; VanderRoest S; Brodfuehrer J
    J Med Chem; 2001 Jul; 44(14):2319-32. PubMed ID: 11428926
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nonpeptidic HIV protease inhibitors: 6-alkyl-5,6-dihydropyran-2-ones possessing a novel and achiral 3-(2-t-butyl-5-methyl-4-sulfamate)phenylthio moiety.
    Vara Prasad JV; Markoski LJ; Boyer FE; Domagala JM; Ellsworth EL; Gajda C; Hagen SE; Tait BD; Lunney EA; Tummino PJ; Ferguson D; Holler T; Hupe D; Nouhan C; Gracheck SJ; VanderRoest S; Saunders J; Iyer K; Sinz M
    Bioorg Med Chem Lett; 1999 Aug; 9(15):2217-22. PubMed ID: 10465549
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tipranavir (PNU-140690): a potent, orally bioavailable nonpeptidic HIV protease inhibitor of the 5,6-dihydro-4-hydroxy-2-pyrone sulfonamide class.
    Turner SR; Strohbach JW; Tommasi RA; Aristoff PA; Johnson PD; Skulnick HI; Dolak LA; Seest EP; Tomich PK; Bohanon MJ; Horng MM; Lynn JC; Chong KT; Hinshaw RR; Watenpaugh KD; Janakiraman MN; Thaisrivongs S
    J Med Chem; 1998 Aug; 41(18):3467-76. PubMed ID: 9719600
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structure-based design of HIV protease inhibitors: 4-hydroxycoumarins and 4-hydroxy-2-pyrones as non-peptidic inhibitors.
    Thaisrivongs S; Tomich PK; Watenpaugh KD; Chong KT; Howe WJ; Yang CP; Strohbach JW; Turner SR; McGrath JP; Bohanon MJ
    J Med Chem; 1994 Sep; 37(20):3200-4. PubMed ID: 7932546
    [No Abstract]   [Full Text] [Related]  

  • 17. Inhibitors of HIV protease: unique non-peptide active site templates.
    Tait BD; Domagala J; Ellsworth EL; Ferguson D; Gajda C; Hupe D; Lunney EA; Tummino PJ
    J Mol Recognit; 1996; 9(2):139-42. PubMed ID: 8877805
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Competitive inhibition of HIV-1 protease by 4-hydroxy-benzopyran-2-ones and by 4-hydroxy-6-phenylpyran-2-ones.
    Tummino PJ; Ferguson D; Hupe L; Hupe D
    Biochem Biophys Res Commun; 1994 May; 200(3):1658-64. PubMed ID: 8185622
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structure-based design of nonpeptidic HIV protease inhibitors: the sulfonamide-substituted cyclooctylpyramones.
    Skulnick HI; Johnson PD; Aristoff PA; Morris JK; Lovasz KD; Howe WJ; Watenpaugh KD; Janakiraman MN; Anderson DJ; Reischer RJ; Schwartz TM; Banitt LS; Tomich PK; Lynn JC; Horng MM; Chong KT; Hinshaw RR; Dolak LA; Seest EP; Schwende FJ; Rush BD; Howard GM; Toth LN; Wilkinson KR; Romines KR
    J Med Chem; 1997 Mar; 40(7):1149-64. PubMed ID: 9089336
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structure-based QSAR analysis of a set of 4-hydroxy-5,6-dihydropyrones as inhibitors of HIV-1 protease: an application of the receptor-dependent (RD) 4D-QSAR formalism.
    Santos-Filho OA; Hopfinger AJ
    J Chem Inf Model; 2006; 46(1):345-54. PubMed ID: 16426069
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.